2023
Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors. British Journal Of Dermatology 2023, 190: 138-138. PMID: 37947404, DOI: 10.1093/bjd/ljad342.Peer-Reviewed Original ResearchMalignant blue nevus: Characterization of US epidemiology and prognostic factors of a rare neoplasm with aggressive clinical course using the Surveillance, Epidemiology, and End Results Program database
Yumeen S, Mirza F, Mirza H, Zogg C, Leventhal J, Cohen J. Malignant blue nevus: Characterization of US epidemiology and prognostic factors of a rare neoplasm with aggressive clinical course using the Surveillance, Epidemiology, and End Results Program database. Journal Of The American Academy Of Dermatology 2023, 89: 843-846. PMID: 37343827, DOI: 10.1016/j.jaad.2023.05.090.Peer-Reviewed Original ResearchHistopathologic features and immunohistochemistry findings to assist the dermatopathologist in differentiating melanocytic matrical carcinoma from melanoma
Belzer A, Becerra C, Clune J, Malik M, Leventhal J, Cowper S, Johnson R. Histopathologic features and immunohistochemistry findings to assist the dermatopathologist in differentiating melanocytic matrical carcinoma from melanoma. Journal Of Cutaneous Pathology 2023, 50: 471-474. PMID: 36645720, DOI: 10.1111/cup.14376.Peer-Reviewed Original Research
2021
Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma
Pach J, Olamiju B, Weiss S, Damsky W, Leventhal J. Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma. JAMA Dermatology 2021, 157: 468-469. PMID: 33688919, DOI: 10.1001/jamadermatol.2021.0058.Peer-Reviewed Original Research
2020
Association between halo nevi and melanoma in adults: A multicenter retrospective case series
Haynes D, Strunck JL, Said J, Tam I, Varedi A, Topham CA, Olamiju B, Wei BM, Erickson MK, Wang LL, Tan A, Stoner R, Hartman RI, Lilly E, Grossman D, Curtis JA, Westerdahl JS, Leventhal JS, Choi JN, Chu EY, Ming ME, Stein JA, Liebman TN, Berry E, Greiling TM. Association between halo nevi and melanoma in adults: A multicenter retrospective case series. Journal Of The American Academy Of Dermatology 2020, 84: 1164-1166. PMID: 32822787, DOI: 10.1016/j.jaad.2020.08.056.Peer-Reviewed Original ResearchNear total body vitiligo secondary to immunotherapy for metastatic melanoma
Olamiju B, Leventhal J. Near total body vitiligo secondary to immunotherapy for metastatic melanoma. British Journal Of Dermatology 2020, 183: e2-e2. PMID: 32147813, DOI: 10.1111/bjd.18944.Peer-Reviewed Case Reports and Technical Notes
2019
B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
Damsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Journal For ImmunoTherapy Of Cancer 2019, 7: 153. PMID: 31200747, PMCID: PMC6567557, DOI: 10.1186/s40425-019-0613-1.Peer-Reviewed Original ResearchConceptsPD-1 inhibitorsB cell contentB-cell depletionAnti-tumor activityB cellsMuMT miceCell depletionAnti-PD-1 inhibitorsAnti-PD-1 responseB-cell depleting drugsTumor-infiltrating B cellsImpaired B-cell functionT cell-dependent tumor rejectionPD-1 inhibitionMC38 colon cancerB cell functionAnti-tumor effectsB-cell malignanciesMurine cancer modelsCell contentOverall survivalTumor rejectionCD20 antibodyAutoimmune disordersTumor shrinkage
2016
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy
Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy. JAMA Dermatology 2016, 152: 1128-1136. PMID: 27411054, PMCID: PMC6108080, DOI: 10.1001/jamadermatol.2016.2226.Peer-Reviewed Original ResearchConceptsAnti-PD-1/PD-L1 therapyCutaneous adverse effectsPD-L1 therapyCell death 1Concurrent medicationsDeath-1Adverse effectsClinical morphologyAnti-PD-1/PD-L1 treatmentAnti-programmed cell death ligand-1 (PD-L1) immunotherapiesAnti-programmed cell death 1Non-small cell lung cancerDeath ligand 1 (PD-L1) immunotherapyPD-L1 antibody therapyCell death ligand 1Yale-New Haven HospitalMucocutaneous adverse effectsPD-L1 treatmentTreatment of rashTertiary care hospitalDeath ligand 1Lichenoid drug eruptionCell lung cancerSkin biopsy specimensRecent US Food
2015
100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series
Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series. Journal Of The American Academy Of Dermatology 2015, 73: 645-654. PMID: 26259990, DOI: 10.1016/j.jaad.2015.06.060.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, TopicalAminoquinolinesCohort StudiesDrug Therapy, CombinationFemaleFollow-Up StudiesHumansImiquimodInjections, IntralesionalInterleukin-2MaleMelanomaNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingRetinoidsRetrospective StudiesRisk AssessmentSkin NeoplasmsTreatment OutcomeConceptsIntralesional IL-2Cutaneous melanoma metastasesCutaneous metastatic melanomaIL-2Topical imiquimodMetastatic melanomaMelanoma metastasesCase seriesUS National Comprehensive Cancer Network guidelinesCommon treatment-related adverse eventsResponse rateNational Comprehensive Cancer Network guidelinesTreatment-related adverse eventsComplete response rateRetrospective case seriesPromising therapeutic optionLocal response rateAdverse eventsRetrospective reviewSurgical excisionNetwork guidelinesTherapeutic optionsCombination therapyBiopsy specimensRetinoid cream